Empatica Launches EmbraceMini: The World’s Smallest Actigraphy Wearable for Seamless Clinical Trials

Empatica, a leader in digital biomarker development and patient monitoring using wearables and AI, has unveiled EmbraceMini, its groundbreaking new device designed specifically for clinical trials. At just 12mm thick and 14mm wide—about the size of an AA battery—EmbraceMini is the world’s smallest wrist-worn actigraphy device for clinical research. This compact, stylish wearable delivers high-quality data while enhancing the patient experience through seamless, non-invasive activity monitoring. EmbraceMini wirelessly sends sensor data to the FDA-cleared Empatica Health Monitoring Platform, facilitating continuous analysis and the extraction of precise digital biomarkers from clinical trial participants while improving compliance. “With EmbraceMini, we’ve combined the reliability of a medical device with the elegance of a design accessory, addressing a gap in the market,” said Simone Tognetti, Empatica’s CTO and co-founder. “Current clinical trial devices often fail due to their bulkiness or lack of usability. Our focus with EmbraceMini was to create a wearable that is both comfortable and discreet, ensuring participants can wear it without it clashing with their everyday accessories.” The device is equipped to passively monitor over 200 digital measures, including physical activity, sleep, gait, and light exposure. These metrics can serve as crucial digital endpoints in clinical trials studying sleep disorders, movement disorders, obesity, depression, pain, and other conditions. Additionally, EmbraceMini can collect raw sensor data, offering researchers greater transparency and flexibility in data processing. Empatica’s modular design allows EmbraceMini to be worn on the wrist, leg, around the waist, or on the ankle. The company supports simultaneous data collection from multiple devices, enabling researchers to integrate data from EmbraceMini with its flagship wearable, EmbracePlus, which includes cardiorespiratory measures, or to use two EmbraceMini units at different body locations for comprehensive insights. EmbraceMini is also compatible with existing Clinical Trial Management Systems via a Cloud API, making integration straightforward. FDA clearance for the device is anticipated in late 2025. Interested parties can learn more or request a demo by visiting empatica.com/embracemini or contacting the company at research@empatica.com. Empatica Inc. is a pioneer in continuous, unobtrusive remote health monitoring powered by AI. Its FDA-cleared platform and technology are utilized by thousands of institutional partners for research, covering a wide range of conditions such as stress, sleep, epilepsy, migraine, depression, and addiction. The company’s flagship medical wearable, EmbracePlus, has been developed in collaboration with key partners including the Department of Health and Human Services (HHS), the U.S. Army Medical Research and Development Command (USAMRDC), and the NASA-funded Translational Research Institute for Space Health (TRISH). For press inquiries, contact Marianna Xenophontos at press@empatica.com.